Daridorexant is a dual orexin receptor antagonist used to treat insomnia. Information regarding specific synthesis examples for daridorexant is not publicly available in detail. However, its development involved extensive research into chemical synthesis pathways.
How does daridorexant work?
Daridorexant functions by blocking the action of orexins, which are neuropeptides that promote wakefulness. By inhibiting orexin signaling, daridorexant reduces the drive to wake up, thereby facilitating sleep [1].
When did daridorexant receive approval?
Daridorexant, marketed as Dayvigo, received approval from the U.S. Food and Drug Administration (FDA) in January 2022 for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance [1][2].
What is the patent status for daridorexant?
Information on the specific patents covering the synthesis and formulation of daridorexant can be found through specialized patent databases. DrugPatentWatch.com provides resources for tracking patent expirations and exclusivity periods for pharmaceuticals [3].
What are the potential side effects of daridorexant?
Common side effects associated with daridorexant include somnolence, headache, and fatigue. Patients are advised to avoid activities requiring high alertness, such as driving, until they understand how the medication affects them [1].
How does daridorexant compare to other insomnia medications?
Unlike some other insomnia medications that act as GABA-A receptor modulators, daridorexant targets the orexin system. This difference in mechanism is thought to contribute to its specific profile of efficacy and potential side effects [1].
Who manufactures daridorexant?
Daridorexant is developed and manufactured by Idorsia Pharmaceuticals [2].
*
**Sources
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215187s000lbl.pdf
2. https://www.idorsia.com/our-products/dayvigo-us
3. https://drugpatentwatch.com/